Highlight
– Tandem CD19/CD22 CAR T-cell therapy achieved complete remission in 80% of heavily pretreated pediatric and young adult patients with r/r B-ALL at 28 days post-infusion.
– Combination with consolidative hematopoietic stem cell transplantation (HSCT) yielded an 18-month overall survival of 70%.
– High-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) correlated with preinfusion high tumor burden (TB), emphasizing the need for effective bridging therapy.
